Page last updated: 2024-08-22

lutetium and Neuroendocrine Tumors

lutetium has been researched along with Neuroendocrine Tumors in 103 studies

Research

Studies (103)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (5.83)	29.6817
2010's	65 (63.11)	24.3611
2020's	32 (31.07)	2.80

Authors

Authors	Studies
Argiroffi, G; Baccini, M; Centonze, G; Fuoco, V; Garanzini, EM; Gherardini, L; Kirienko, M; Maccauro, M; Milione, M; Prinzi, N; Pusceddu, S; Scalorbi, F; Seregni, E	1
de Vries-Huizing, DMV; de Wit-van der Veen, BJ; Geluk-Jonker, MM; Hendrikx, JJMA; Sinaasappel, M; Stokkel, MPM; Tesselaar, MET; Versleijen, MWJ; Walraven, I	1
Bober, B; Brodowska-Kania, D; Kaminski, G; Kapusta, W; Kolodziej, M; Lubas, A; Saracyn, M	1
Berry, K; Kendrick, J	1
Davidson, J; Hull, A; Lunt, B; Mead, T; Stewart, A	1
Almeamar, H; Crowley, RK; Cullen, L; Murphy, DJ; O'Shea, D; O'Toole, D; Toumpanakis, C; Welin, S	1
Abraham, T; Banks, KP; Bodei, L; Boike, T; Brown, RKJ; Bushnell, DL; DeBlanche, LE; Desai, NB; Dominello, MM; Francis, T; Grady, EC; Hobbs, RF; Hope, TA; Kempf, JS; Love, C; Pryma, DA; Rule, W; Savir-Baruch, B; Schechter, NR; Sethi, I; Subramaniam, RM; Xiao, Y	2
Bodei, L; Capanu, M; Choi, Y; Chou, JF; Coffman, K; Do, RKG; Dunphy, M; Fox, JJ; Grewal, RK; Le, T; Rafailov, J; Raj, N; Reddy, RP; Reidy-Lagunes, D; Riedl, C; Schoder, H	1
Aparici, CM; Duan, H; Fischer, GA; Shaheen, S; Somoza, EA	1
Bagni, O; D'Agostini, A; Filippi, L; Pirisino, R	1
Barakat, A; Deshayes, E; Khier, S; Kotzki, PO; Santoro, L; Vivien, M	1
Bodei, L; Gönen, M; Krebs, S; Lewis, JS; Lohrmann, C; Lyashchenko, SK; O'Donoghue, JA; Pandit-Taskar, N; Raj, N; Reidy-Lagunes, D; Staton, KD; Weber, WA	1
Baum, RP; Liu, C; Liu, T; Yang, Z; Zhang, J	1
Baum, RP; Kulkarni, HR; Singh, A; Zhang, J	1
Barentsz, MW; Braat, AJAT; Ebbers, SC; Lam, MGEH; Moelker, A; Stokkel, MPM	1
Fidelman, N	1
Cordes, M; Goetz, TI; Kuwert, T; Lang, EW; Maier, A; Prante, O; Ritt, P; Schmidkonz, C	1
Bodeker, KL; Bushnell, DL	1
Chitwood, H; Myers, A	1
Martins, H; Moreira, AP; Silva, R; Soeiro, P	1
Clift, AK; Frilling, A	1
Bilha, SC; Constantin, V; Covic, A; Matovic, M; Nistor, I; Simona, V; Stefanescu, C; Stolniceanu, CR	1
Cullinane, C; Eu, P; Hicks, RJ; Kirby, L; Rogers, BE; Tothill, RW; Waldeck, K	1
Alapati, N; Ali, AZ; Digumarti, R; Manasa, N; Vallathol, DH; Vasanth, P	1
Ercaliskan, A; Eskazan, AE; Kabasakal, L; Kucukyurt, S; Yagiz Ozogul, Y	1
Blachier, M; Leeuwenkamp, O; Ortiz, R; Smith-Palmer, J; Valentine, W; Walter, T; Werner, A	1
Bolzati, C; Duatti, A	1
Baum, RP; Hommann, M; Hörsch, D; Kaemmerer, D; Kulkarni, HR; Sehner, S; Twrznik, M	1
Leeuwenkamp, OR; Reed, N; Smith-Palmer, J; Virk, J	1
Berlin, J; Bradshaw, M; Cardin, D; Ciombor, K; Das, S; Delbeke, D; Du, L; Eisner, D; Goff, L; Jain, S; Jessop, A; Sandler, M; Schad, A; Shah, C	1
Boersma, C; Hagendijk, ME; Postma, MJ; van der Pol, S; van der Schans, S	1
Bartolomei, M; Iannicelli, E; Magi, L; Panareo, S; Panzuto, F; Prosperi, D; Rinzivillo, M	1
Arnold, S; Sturchio, G; Underwood, J	1
Alenezi, SA; Dannoon, SF; Elgazzar, AH	1
Hatazawa, J; Hosono, M; Ikebuchi, H; Inoue, T; Kinuya, S; Kitaoka, A; Kojima, K; Nakamura, N; Nakamura, Y; Sugano, H; Yamada, T; Yanagida, S	1
Dalmo, J; Forssell-Aronsson, E; Helou, K; Langen, B; Nilsson, O; Parris, TZ; Rudqvist, N; Schüler, E; Spetz, J; Wängberg, B	1
Turner, JH	1
Ćwikła, JB; Kolasińska-Ćwikła, A; Maciejkiewicz, KM; Łowczak, A	1
Bandara, N; Chen, X; Jacobson, O; Mpoy, C; Rogers, BE	1
Delpassand, ES; Hendifar, AE; Kittleson, MM; Tuli, R	1
Boucher, JE; Sommers, R	1
Berntzen, DT; Løitegård, T; Thiis-Evensen, E	1
Blažević, A; Brabander, T; de Herder, WW; Feelders, RA; Hofland, J; Kam, BLR; Teunissen, JJM; Zandee, WT	1
Almobarak, B; Altiparmak, G; Arvidsson, Y; Elf, AK; Elias, E; Forssell-Aronsson, E; Hofving, T; Johanson, V; Kristiansson, E; Nilsson, O; Sandblom, V; Shubbar, E; Swanpalmer, J	1
Courbon, F; Dierickx, L; Vija, L	1
Brabander, T; Hofland, J; Nonnekens, J	1
Bajwa, A; McEwan, AJB; McMullen, TPW; Paterson, J; Saravana-Bawan, B	1
Banks, M; Cuthbertson, DJ; Daousi, C; Dobson, R; Hsuan, J; Poston, GP; Terlizzo, M; Vinjamuri, S; Wieshmann, H	1
Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ	1
Li, H; Tang, K; Wang, L; Wen, Z; Zhang, H; Zhang, Q	1
Bruchertseifer, F; Fahrer, J; Fottner, C; Graf, F; Huelsenbeck, J; Kaina, B; Maus, S; Miederer, M; Morgenstern, A; Schreckenberger, M; Venkatachalam, S; Weber, MM	1
Calais, PJ; Turner, JH	1
Banerjee, S; Das, T; Kamaleshwaran, KK; Sarma, HD; Shinto, A	1
Del Pozzo, L; Fani, M; Fischer, R; Kaul, F; Krebs, S; Maecke, HR; Reubi, JC; Rivier, JE; Weber, WA; Wild, D	1
Allen-Auerbach, MS; Bluemel, C; Herrmann, K; Higuchi, T; Werner, RA	1
Baum, RP; Bodei, L; Cremonesi, M; Drozdov, I; Grana, CM; Kidd, M; Krenning, EP; Kwekkeboom, DJ; Lepensky, C; Modlin, IM; Paganelli, G	1
Hicks, RJ	1
Cruz, K; Olmstead, C; Stodilka, R; Wolfson, R; Zabel, P	1
Carollo, A; Chinol, M; Papi, S	1
Brolin, G; Gleisner, KS; Larsson, E; Mjekiqi, E; Östlund, K; Sundlöv, A; Tennvall, J	1
Claringbold, PG; Turner, JH	1
Abdülrezzak, Ü; Buyukkaya, F; Karaca, H; Kula, M; Tutuş, A	1
Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G	1
Bergsma, H; de Herder, WW; Franssen, GJ; Kam, BL; Konijnenberg, MW; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; van Eijck, CH	1
Bodei, L; Botta, F; Cremonesi, M; D'Errico, V; Ferrari, M; Fioroni, F; Grassi, E; Guerriero, F; Orecchia, R; Paganelli, G; Sarnelli, A; Strigari, L	1
Andresen, TL; Binderup, T; Elema, DR; Hag, AM; Henriksen, JR; Kjær, A; Petersen, AL; Rasmussen, PH	1
Cives, M; Soares, HP; Strosberg, J	1
Bodei, L; Chiti, A; Cremonesi, M; Ezziddin, S; Forrer, F; Hicks, RJ; Kidd, M; Luster, M; Modlin, IM	1
Kesavan, M; Turner, JH	1
Caldeira Filho, JS; Colturato, MT; Couto, RM; de Araújo, EB; Mengatti, J; Muramoto, E; Nagamati, LT; Pujatti, PB; Silva, CP	1
Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M	1
Garkavij, M; Ljungberg, M; Nickel, M; Ohlsson, T; Sjögreen-Gleisner, K; Strand, SE; Tennvall, J; Wingårdh, K	1
Bodei, L; Paganelli, G; Pepe, G	1
Cescato, R; Fani, M; Maecke, HR; Mueller, A; Nicolas, G; Reubi, JC; Rink, HR; Tamma, ML	1
de Herder, WW; Krenning, EP; Kwekkeboom, DJ	1
Forrer, F; Giovacchini, G; Müller-Brand, J; Nicolas, G	1
Dabasi, G; Igaz, P; Kender, Z; Rácz, K; Reismann, P; Sréter, L	1
Hubalewska-Dydejczyk, A; Królicki, L; Kunikowska, J; Mikołajczak, R; Pawlak, D; Sowa-Staszczak, A	1
Brans, B; Kessels, A; Mottaghy, FM	1
Głowa, B; Hubalewska-Dydejczyk, AB; Jabrocka-Hybel, A; Królicki, L; Kunikowska, J; Mikołajczak, R; Pach, D; Pawlak, D; Sowa-Staszczak, A; Stefańska, A; Tomaszuk, M; Trofimiuk, M	1
Barber, TW; Hicks, RJ; Hofman, MS; Thomson, BN	1
Bardiès, M; Chiesa, C; Chiti, A; Flux, G; Konijnenberg, M; Lassmann, M; Reijonin, V; Savolainen, S; Strigari, L	1
Baio, SM; Bodei, L; Chinol, M; Cremonesi, M; Grana, CM; Paganelli, G; Severi, S	1
de Herder, WW; Kam, BL; Khan, S; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; van Vliet, EI	1
Briel, M; Brunner, P; Koller, MT; Mäcke, HR; Marincek, N; Müller-Brand, J; Ng, QK; Rochlitz, C; Romer, A; Schindler, C; Villard, L; Walter, MA	1
Kwekkeboom, DJ	1
Fottner, C; Helisch, A; Miederer, M; Reber, H; Schreckenberger, M; Weber, M	1
Bartenstein, P; Baum, RP; Bengel, FM; Biersack, HJ; Dunkelmann, S; Ezziddin, S; Gratz, KF; Haug, A; Hörsch, D; Knapp, WH; Krause, BJ; Plöckinger, U; Schümichen, C; Schwartz-Fuchs, S	1
Hubalewska-Dydejczyk, A; Sowa-Staszczak, A; Tomaszuk, M	1
Cwikla, J; Gut, P; Handkiewicz-Junak, D; Hubalewska-Dydejczyk, A; Jakuciński, M; Kamiński, G; Kowalska, A; Królicki, L; Kunikowska, J; Lukiewicz, A; Mikolajczak, R; Pawlak, D; Sowa-Staszczak, A; Szaluś, N	1
Baum, RP; Hommann, M; Kaemmerer, D; Prasad, V; Todorović-Tirnanić, M	1
Kairemo, K; Kangasmäki, A	1
Baum, RP; Kulkarni, HR; Müller, D; Prasad, V; Schuchardt, C; Zachert, C	1
Baum, RP; Kulkarni, HR; Schuchardt, C	1
Baum, RP; Kulkarni, HR; Prasad, V; Schuchardt, C	1
Baechler, S; Boubaker, A; Dieudonné, A; Gardin, I; Hobbs, RF; Le Guludec, D; Lebtahi, R; Maurel, F; Sgouros, G; Wahl, RL	1
Mikolajczak, R; Parus, JL	1
Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ	1
deHerder, WW; deJong, M; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R	1
de Herder, WW; de Keizer, B; Feelders, RA; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M	1
Bakker, WH; Breeman, WA; de Jong, M; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Valkema, R; Visser, TJ	1

Reviews

21 review(s) available for lutetium and Neuroendocrine Tumors

Article	Year
Overview and Current Status of Peptide Receptor Radionuclide Therapy. Surgical oncology clinics of North America, 2020, Volume: 29, Issue:2 Topics: Animals; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Stomach Neoplasms	2020
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Nuclear medicine communications, 2020, Volume: 41, Issue:7 Topics: Humans; Isotope Labeling; Kidney; Lutetium; Neuroendocrine Tumors; Radioisotopes; Renal Insufficiency; Somatostatin; Yttrium Radioisotopes	2020
The emerging value of 64Cu for molecular imaging and therapy. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2020, Volume: 64, Issue:4 Topics: Antigens, Surface; Chelating Agents; Coordination Complexes; Copper Radioisotopes; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Humans; Iodine Radioisotopes; Lutetium; Male; Molecular Imaging; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin	2020
The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis. Nuclear medicine communications, 2017, Volume: 38, Issue:12 Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide; Treatment Outcome; Yttrium Radioisotopes	2017
Recent advances in theranostics and challenges for the future. The British journal of radiology, 2018, Volume: 91, Issue:1091 Topics: Clinical Trials as Topic; Dipeptides; Forecasting; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Molecular Targeted Therapy; Neuroendocrine Tumors; Peptides, Cyclic; Prostate-Specific Antigen; Prostatic Neoplasms; Radioactive Tracers; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Theranostic Nanomedicine	2018
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Nuclear medicine review. Central & Eastern Europe, 2018, Volume: 21, Issue:2 Topics: Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Receptors, Peptide; Stomach Neoplasms; Yttrium Radioisotopes	2018
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors. The Medical letter on drugs and therapeutics, 2018, Sep-10, Volume: 60, Issue:1555 Topics: Animals; Clinical Trials as Topic; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides, Cyclic; Protein Binding; Stomach Neoplasms	2018
The next generation of peptide receptor radionuclide therapy. Endocrine-related cancer, 2019, Volume: 26, Issue:8 Topics: Animals; HSP90 Heat-Shock Proteins; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Treatment Outcome	2019
Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis. Clinical nuclear medicine, 2019, Volume: 44, Issue:9 Topics: Humans; Lutetium; Neoadjuvant Therapy; Neuroendocrine Tumors; Prognosis; Radioisotopes; Receptors, Peptide	2019
Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. BioMed research international, 2013, Volume: 2013 Topics: Humans; Lutetium; Molecular Imaging; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2013
68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Annals of nuclear medicine, 2015, Volume: 29, Issue:1 Topics: Gallium Radioisotopes; Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2015
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Current opinion in oncology, 2016, Volume: 28, Issue:4 Topics: Clinical Trials, Phase III as Topic; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Somatostatin; Stomach Neoplasms	2016
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. Cancer biotherapy & radiopharmaceuticals, 2016, Volume: 31, Issue:6 Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Temozolomide	2016
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. European review for medical and pharmacological sciences, 2010, Volume: 14, Issue:4 Topics: Antineoplastic Agents; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Yttrium Radioisotopes	2010
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1 Topics: Animals; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2011
Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1 Topics: Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Radiation Injuries; Radioisotopes; Radionuclide Imaging; Radiotherapy; Somatostatin; Yttrium Radioisotopes	2011
Yttrium-labelled peptides for therapy of NET. European journal of nuclear medicine and molecular imaging, 2012, Volume: 39 Suppl 1 Topics: Bone Marrow; Clinical Trials as Topic; Humans; Kidney; Lutetium; Neuroendocrine Tumors; Octreotide; Peptides; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Peptide; Safety; Treatment Outcome; Yttrium Radioisotopes	2012
Lutetium-labelled peptides for therapy of neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 2012, Volume: 39 Suppl 1 Topics: Disease-Free Survival; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Somatostatin	2012
Beta-emitting radionuclides for peptide receptor radionuclide therapy. Current topics in medicinal chemistry, 2012, Volume: 12, Issue:23 Topics: Beta Particles; Chelating Agents; Humans; Isotope Labeling; Ligands; Lutetium; Neuroendocrine Tumors; Radioactivity; Radioisotopes; Radionuclide Imaging; Radiotherapy; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2012
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. Journal of endocrinological investigation, 2005, Volume: 28, Issue:11 Suppl I Topics: Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2005
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. European journal of nuclear medicine, 2001, Volume: 28, Issue:9 Topics: Humans; Indium Radioisotopes; Lutetium; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2001

Trials

6 trial(s) available for lutetium and Neuroendocrine Tumors

Article	Year
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23 Topics: Adult; Aged; Chelating Agents; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Prognosis; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Young Adult	2019
Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials, 2020, Feb-05, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Coordination Complexes; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver; Liver Neoplasms; Lutetium; Male; Multicenter Studies as Topic; Neuroendocrine Tumors; Octreotide; Radioisotopes; Randomized Controlled Trials as Topic; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome	2020
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Leukemia, Myeloid, Acute; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes	2015
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. Cancer biotherapy & radiopharmaceuticals, 2015, Volume: 30, Issue:6 Topics: Adult; Aged; Everolimus; Female; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Radionuclide Imaging; Treatment Outcome	2015
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:10 Topics: Adult; Aged; Disease-Free Survival; Endpoint Determination; Female; Humans; Lutetium; Male; Middle Aged; Molecular Imaging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiotherapy; Tumor Burden	2011
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13 Topics: Adult; Aged; Female; Health Status; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Quality of Life; Receptors, Peptide; Receptors, Somatostatin; Stomach Neoplasms; Treatment Outcome	2004

Other Studies

76 other study(ies) available for lutetium and Neuroendocrine Tumors

Article	Year
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Scientific reports, 2021, 09-30, Volume: 11, Issue:1 Topics: Aged; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lutetium; Male; Middle Aged; Models, Theoretical; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Prognosis; Radioisotopes; Radiopharmaceuticals; Renal Insufficiency	2021
Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course. PloS one, 2021, Volume: 16, Issue:11 Topics: Aged; Female; Gallium Radioisotopes; Hemolytic Agents; Humans; Leukocytes; Lutetium; Male; Middle Aged; Netherlands; Neuroendocrine Tumors; Neutrophils; Octreotide; Organometallic Compounds; Platelet Count; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies	2021
Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm. Nuclear medicine review. Central & Eastern Europe, 2022, Volume: 25, Issue:1 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Receptors, Peptide; Yttrium Radioisotopes	2022
Lutetium-177 Radiopharmeceutical Therapy Extravasation Lessons Learned. Health physics, 2022, 08-01, Volume: 123, Issue:2 Topics: Humans; Lutetium; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals	2022
Evaluation of radiation safety of the newly established national New Zealand 177-Lutetium (177-Lu or Lutate) Peptide Receptor Radiation Therapy (PRRT) service, a palliative treatment for patients with metastatic neuroendocrine tumours. Journal of medical imaging and radiation sciences, 2022, Volume: 53, Issue:2 Suppl Topics: Humans; Lutetium; Neuroendocrine Tumors; New Zealand; Palliative Care; Receptors, Peptide	2022
Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours. Journal of neuroendocrinology, 2022, Volume: 34, Issue:6 Topics: Aged; Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide; Retrospective Studies; Somatostatin	2022
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. American journal of clinical oncology, 2022, 06-01, Volume: 45, Issue:6 Topics: Adult; Humans; Lutetium; Neuroendocrine Tumors; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals	2022
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Clinical nuclear medicine, 2022, Jun-01, Volume: 47, Issue:6 Topics: Adult; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals	2022
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE. Neuroendocrinology, 2022, Volume: 112, Issue:12 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals	2022
Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177 Lu-DOTATATE. Clinical nuclear medicine, 2022, 11-01, Volume: 47, Issue:11 Topics: Aged; Carcinoma, Neuroendocrine; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide	2022
Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE. Clinical nuclear medicine, 2022, 11-01, Volume: 47, Issue:11 Topics: Aged; Female; Humans; Intestinal Neoplasms; Lutetium; Meningeal Neoplasms; Meningioma; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Stomach Neoplasms	2022
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera European journal of drug metabolism and pharmacokinetics, 2023, Volume: 48, Issue:4 Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed	2023
Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy. Clinical nuclear medicine, 2019, Volume: 44, Issue:11 Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Peptide; Treatment Outcome	2019
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist. Clinical nuclear medicine, 2020, Volume: 45, Issue:3 Topics: Adult; Female; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals	2020
Holmium-166 radioembolisation after peptide receptor radionuclide therapy: much needed data to help inform future research. The Lancet. Oncology, 2020, Volume: 21, Issue:4 Topics: Holmium; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide	2020
Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent Annals of nuclear medicine, 2020, Volume: 34, Issue:4 Topics: Aged; Antineoplastic Agents; Chromogranin A; Female; Humans; Lutetium; Male; Middle Aged; Monte Carlo Method; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome	2020
Peptide Receptor Radionuclide Therapy: An Emerging Treatment for Gastrointestinal Neuroendocrine Tumors. Clinical journal of oncology nursing, 2020, 04-01, Volume: 24, Issue:2 Topics: Adult; Coordination Complexes; Female; Gastrointestinal Neoplasms; Humans; Lutetium; Neuroendocrine Tumors; Nurses; Octreotide; Receptors, Peptide	2020
Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy. BMJ case reports, 2020, Mar-31, Volume: 13, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Humans; Liver Neoplasms; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Receptors, Peptide; Remission Induction	2020
Combining radiolabelled therapies for neuroendocrine neoplasms. Nature reviews. Endocrinology, 2020, Volume: 16, Issue:7 Topics: Holmium; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Radioisotopes	2020
Enhancing the anti-tumour activity of Scientific reports, 2020, 06-23, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Lutetium; Mice; Mice, Inbred BALB C; Mice, Nude; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin	2020
Lutetium 177 dotatate induced acute myeloid leukemia. Leukemia & lymphoma, 2020, Volume: 61, Issue:13 Topics: Humans; Leukemia, Myeloid, Acute; Lutetium; Neuroendocrine Tumors; Radiopharmaceuticals	2020
Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. Cancer reports (Hoboken, N.J.), 2020, Volume: 3, Issue:5 Topics: Bone Marrow; Chemoradiotherapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radioisotopes; Sunitinib	2020
Cost-effectiveness of Lutetium [ Journal of medical economics, 2020, Volume: 23, Issue:12 Topics: Cost-Benefit Analysis; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide	2020
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms. Annals of surgery, 2021, 07-01, Volume: 274, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2021
Lutetium oxodotreotide ( BMC cancer, 2021, Jan-05, Volume: 21, Issue:1 Topics: Cost-Benefit Analysis; Disease Progression; Follow-Up Studies; Humans; Intestinal Neoplasms; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Radiopharmaceuticals; Stomach Neoplasms	2021
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy. Endocrine-related cancer, 2021, Volume: 28, Issue:3 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging	2021
Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. The European journal of health economics : HEPAC : health economics in prevention and care, 2021, Volume: 22, Issue:6 Topics: Cost-Benefit Analysis; Humans; Lutetium; Netherlands; Neuroendocrine Tumors; Octreotide; Orphan Drug Production; Quality-Adjusted Life Years	2021
Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response. Oncology research and treatment, 2021, Volume: 44, Issue:5 Topics: Humans; Lutetium; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide; Retreatment	2021
Patient Release and Instructions for Lutetium Dotatate Radiopharmaceutical Therapy. Health physics, 2021, 08-01, Volume: 121, Issue:2 Topics: Humans; Lutetium; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiation Exposure; Radionuclide Imaging; Radiopharmaceuticals	2021
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Annals of nuclear medicine, 2018, Volume: 32, Issue:3 Topics: Health Personnel; Humans; Japan; Lutetium; Manuals as Topic; Neuroendocrine Tumors; Nuclear Medicine; Practice Guidelines as Topic; Radiation Protection; Radiopharmaceuticals; Safety	2018
Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after Nuclear medicine and biology, 2018, Volume: 60 Topics: Animals; Aspartate Aminotransferase, Cytoplasmic; Female; Intestinal Neoplasms; Intestine, Small; Lutetium; Mice; Mice, Nude; Neuroendocrine Tumors; Octreotide; Radioisotopes; Signal Transduction; Time Factors; Transaminases; Transcription, Genetic; Tumor Suppressor Protein p53	2018
Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent. Bioconjugate chemistry, 2018, 07-18, Volume: 29, Issue:7 Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Evans Blue; Heterografts; Humans; Lutetium; Mice; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Theranostic Nanomedicine; Tissue Distribution; Tomography, Emission-Computed, Single-Photon	2018
Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy. Pancreas, 2018, Volume: 47, Issue:8 Topics: Cardiotoxicity; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide	2018
Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors. Clinical journal of oncology nursing, 2018, 10-01, Volume: 22, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Female; Humans; Intestinal Neoplasms; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms	2018
The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms. Annals of nuclear medicine, 2019, Volume: 33, Issue:3 Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Progression-Free Survival; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden	2019
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. The Journal of clinical endocrinology and metabolism, 2019, 04-01, Volume: 104, Issue:4 Topics: Adult; Aged; Coordination Complexes; Female; Gastrins; Glucagon; Humans; Insulin; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Quality of Life; Radiation Dosage; Radioisotopes; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Vasoactive Intestinal Peptide	2019
177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocrine-related cancer, 2019, 04-01, Volume: 26, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Female; HSP90 Heat-Shock Proteins; Humans; Lutetium; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Triazoles; Tumor Cells, Cultured	2019
Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy. Annales d'endocrinologie, 2019, Volume: 80, Issue:3 Topics: Clinical Trials, Phase III as Topic; France; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Precision Medicine; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Receptors, Somatostatin	2019
Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-10, Volume: 31, Issue:17 Topics: Aged; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Orbital Neoplasms; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals	2013
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. Endocrine-related cancer, 2013, Volume: 20, Issue:6 Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate	2013
DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PloS one, 2014, Volume: 9, Issue:2 Topics: Actinium; Alpha Particles; Animals; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Breaks, Double-Stranded; Lutetium; Neuroendocrine Tumors; Radioisotopes; Rats; Receptors, Somatostatin	2014
Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors. Annals of nuclear medicine, 2014, Volume: 28, Issue:6 Topics: Cancer Care Facilities; Caregivers; Cohort Studies; Environmental Exposure; Female; Health Personnel; Humans; Lutetium; Male; Neuroendocrine Tumors; Occupational Exposure; Octreotide; Outpatients; Radiation Monitoring; Radioisotopes; Radiometry	2014
Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy. Current radiopharmaceuticals, 2014, Volume: 7, Issue:1 Topics: Adult; Animals; Chromatography, High Pressure Liquid; Freeze Drying; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Quality Control; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Whole Body Imaging	2014
Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:8 Topics: Adult; Aged; Amino Acid Sequence; Feasibility Studies; Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Oligopeptides; Organometallic Compounds; Pilot Projects; Radioisotopes; Radiometry; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome	2014
The difference between medicine and magic is that magicians know what they are doing. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1 Topics: Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Yttrium Radioisotopes	2015
Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol. Nuclear medicine communications, 2015, Volume: 36, Issue:2 Topics: Environmental Exposure; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Outpatients; Radiation Monitoring; Radioisotopes; Safety; Time Factors	2015
Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience. Current radiopharmaceuticals, 2016, Volume: 9, Issue:1 Topics: Chemistry, Pharmaceutical; Humans; Lutetium; Neuroendocrine Tumors; Peptides; Quality of Life; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Somatostatin	2016
Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:7 Topics: Female; Gamma Cameras; Gamma Rays; Humans; Kidney; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Phantoms, Imaging; Radioisotopes; Radiometry; Receptors, Peptide; Spectrophotometry; Spleen; Time Factors	2015
PET/CT and Bremsstrahlung Imaging After 90Y DOTANOC Therapy for Rectal Net With Liver Metastases. Clinical nuclear medicine, 2015, Volume: 40, Issue:10 Topics: Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Yttrium Radioisotopes	2015
Long-term results of PRRT in advanced bronchopulmonary carcinoid. European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:3 Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome	2016
Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:3 Topics: Aged; Bone Marrow; Female; Humans; Iodine; Lutetium; Male; Middle Aged; Netherlands; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prognosis; Prospective Studies; Radiation Injuries; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Peptide; Risk Factors; Treatment Outcome	2016
Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2017, Volume: 61, Issue:2 Topics: Adult; Algorithms; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Models, Biological; Neuroendocrine Tumors; Organs at Risk; Radioisotopes; Radiometry; Radiotherapy; Receptors, Peptide; Yttrium Radioisotopes	2017
In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:5 Topics: Animals; Cell Line, Tumor; Copper Radioisotopes; Humans; Liposomes; Lutetium; Mice; Mice, Nude; Neuroendocrine Tumors; Polyethylene Glycols; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tissue Distribution	2016
Myeloid neoplasms after chemotherapy and PRRT: myth and reality. Endocrine-related cancer, 2016, Volume: 23, Issue:8 Topics: Hematologic Neoplasms; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes	2016
A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2009, Volume: 67, Issue:2 Topics: Animals; Chelating Agents; Heterocyclic Compounds, 1-Ring; Iodine Radioisotopes; Lutetium; Mice; Neuroendocrine Tumors; Pharmacokinetics; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Tissue Distribution	2009
[Peptide receptor radionuclide therapy of neuroendocrine tumors]. Ugeskrift for laeger, 2009, Mar-23, Volume: 171, Issue:13 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes	2009
177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer, 2010, Feb-15, Volume: 116, Issue:4 Suppl Topics: Forecasting; Humans; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage	2010
Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:11 Topics: Animals; Calcium; Cell Transformation, Neoplastic; CHO Cells; Cricetinae; Cricetulus; Drug Design; Enzyme Stability; Female; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; HEK293 Cells; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Mice; Neuroendocrine Tumors; Positron-Emission Tomography; Protein Transport; Radioactive Tracers; Radiography; Receptors, Somatostatin; Somatostatin; Structure-Activity Relationship; Tomography, Emission-Computed, Single-Photon	2010
[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients]. Orvosi hetilap, 2011, Mar-06, Volume: 152, Issue:10 Topics: Adult; Aged; Female; Humans; Hungary; Indium Radioisotopes; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Radioisotopes; Radiotherapy; Receptors, Somatostatin; Remission Induction; Yttrium Radioisotopes	2011
90Y/177Lu-DOTATATE therapy: survival of the fittest? European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:10 Topics: Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiotherapy	2011
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 102, Issue:1 Topics: Aged; Diagnostic Imaging; Disease Progression; Female; Humans; Lutetium; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Receptors, Peptide; Statistics, Nonparametric; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes	2012
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2012, Volume: 38, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Duodenal Neoplasms; Fluorouracil; Humans; Lutetium; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Remission Induction; Research Design; Tomography, X-Ray Computed; Treatment Outcome	2012
Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:3 Topics: Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiotherapy	2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioisotopes; Somatostatin; Yttrium Radioisotopes	2012
Therapy: Neuroendocrine cancer--are two radionuclides better than one? Nature reviews. Endocrinology, 2012, May-01, Volume: 8, Issue:6 Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Somatostatin; Survival Rate; Treatment Outcome; Yttrium Radioisotopes	2012
One single-time-point kidney uptake from OctreoScan correlates with number of desintegrations measured over 72 hours and calculated for the 6.7 hours half-life nuclide (177)Lu. Clinical nuclear medicine, 2012, Volume: 37, Issue:10 Topics: Biological Transport; Female; Half-Life; Humans; Kidney; Kinetics; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organ Size; Radioisotopes; Radiometry; Radionuclide Imaging	2012
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Prospective Studies; Radioisotopes; Receptors, Somatostatin; Registries; Yttrium Radioisotopes	2013
PRRT as neoadjuvant treatment in NET. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Humans; Lutetium; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Receptors, Somatostatin	2013
Polish experience in Peptide receptor radionuclide therapy. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2013
Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Female; Humans; Intraoperative Period; Liver Neoplasms; Lutetium; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, X-Ray Computed	2013
4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Four-Dimensional Computed Tomography; Humans; Lutetium; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Receptors, Somatostatin; Software; Tomography, X-Ray Computed	2013
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Adult; Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Whole-Body Counting	2013
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin	2013
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose? Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Blood Cells; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiation Dosage; Radiopharmaceuticals; Receptors, Somatostatin; Spleen	2013
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:2 Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Imaging, Three-Dimensional; Iodine Radioisotopes; Liver Neoplasms; Lutetium; Lymphoma, Non-Hodgkin; Microspheres; Models, Statistical; Monte Carlo Method; Neuroendocrine Tumors; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Dosage; Yttrium Radioisotopes	2013
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Endocrine System Diseases; Gastrointestinal Neoplasms; Humans; Lutetium; Middle Aged; Neuroectodermal Tumors, Primitive; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Retrospective Studies	2008